Navigation Links
INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA
Date:1/20/2012

BEVERLY, Mass., Jan. 20, 2012 /PRNewswire/ -- INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device. This approval allows the INVOcell to be sold to millions of infertile couples in Brazil and marks a major milestone in the history of the company.  The approval opens the door for INVO Bioscience to one of the largest markets and fastest growing economies in the world with over 190 million people. 

The approval by ANVISA follows the completion of a 40 patient clinical trial conducted in Rio de Janeiro, Brazil. The trial was sponsored and conducted by Dr. Francisco Augusto Colucci Coelho of the Center of Infertility and Fetal Medicine of North Rio de Janeiro, Brazil. The results from Dr. Coelho's trial, along with clinical trial results from Dr. Elkin Lucena of the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, South America were submitted to ANVISA for the purpose of gaining registration and approval for the sale of the INVOcell device in Brazil. As originally announced on January 25, 2011, the trial was designed as a 40 patient clinical trial to establish safety, efficacy and comparative in-vitro fertilization (IVF) measures of the INVOcell device.

"Approval in Brazil is a very important step in the success of INVOcell due to the strength of support in the country by medical thought leaders such as Dr. Coelho," stated Kathleen Karloff, chief executive officer for INVO Bioscience. "Today's announcement paves the way for the more than 125 fertility centers in Brazil to begin offering infertile couples a safe and cost effective solution compared to traditional IVF.  We look forward to working with EcoMed, our distribution partner in Brazil, as they begin ramping up their sales and marketing ef
'/>"/>

SOURCE INVO Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... BerGenBio AS, a biopharmaceutical company ... cancers, today announces that it has raised NOK90 million ... and existing investors. BerGenBio will use the ... its pipeline of innovative cancer therapeutics, in particular an ... BGB324, a first-in-class selective Axl kinase inhibitor, which is ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... , THOUSAND OAKS, Calif., Sept. 21 ... from a Phase 3 trial evaluating denosumab administered subcutaneously versus ... treatment of bone metastases in 1,776 advanced cancer patients with ... myeloma. These results were presented today at the 2009 ...
... MADISON, Conn., Sept 18 Further results from the initial clinical ... treatment for varicose veins, will be delivered on Friday, September 25, ... Philadelphia. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 2Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 3Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 5Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 6Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 7Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 8Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 9ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CREEK, Calif., March 4 Longs Drug,Stores Corporation (NYSE: ... a quarterly cash dividend on common shares of $0.14 per ... the close of,business on March 11, 2008., About the ... (NYSE: LDG ) is one of the most recognized ...
... produced another article [1], which probably marks the opening ... of a further 2.4-year follow-up (after cessation of the ... P) cohort are reported. They concluded that, by the ... newly formed and unvalidated tool used in the WHI ...
... - Second Phase III clinical trial to begin ... 4 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... it has received notice from,the U.S. Food and ... bladder cancer meets the criteria for Fast Track,designation. ...
... continued need for mammograms , , TUESDAY, March 4 (HealthDay News) ... woman stops taking combination hormone replacement therapy, a new study ... issue of the Journal of the American Medical Association ... Initiative (WHI). That trial was halted abruptly in 2002, when ...
... G.,Rendell,s health care team today told a state ... Pennsylvanians continues to grow and, with the,addition of ... there are,funds to pay for providing the uninsured ... the House of Representatives Appropriations,Committee that continuing the ...
... annual KID,HEALTHY--Steps to Healthy Living Campaign, SANTA ... trend of childhood obesity in Southern California schools, ... parents from Los Angeles,Orange, Riverside, San Bernardino, San ... participate in the KID HEALTHY--Steps to Healthy,Living Campaign. ...
Cached Medicine News:Health News:Health risks after cessation of postmenopausal hormone therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 2Health News:Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy 3Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 2Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 3Health News:Governor Rendell's Health Care Reform Cabinet Says Providing Access to Health Care for Pennsylvania's Uninsured is Within Reach 4Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3
... An external computer-enhanced microplate reader ... provides automated flexible and rapid ... for accurate and reliable photometric ... or without shaking before reading) ...
... a number of assay steps for ... simple to use benchtop device. The ... stand-alone device but also provides easy ... and standard add-on modules provide maximum ...
... AP-22 Micro Plate Processor is ... Automated Microplate Analyzer. It has been ... assigned area can be customised according ... Micro Plate Processor is able to ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Medicine Products: